TEPMETKO: A Rising Star in the Treatment of METex14 Skipping NSCLC TEPMETKO emerges as a key player in treating NSCLC with MET exon 14 skipping mutations, offering distinct advantages in the oncology landscape.

TEPMETKO: A Rising Star in the Treatment of METex14 Skipping NSCLC #USA #Las_Vegas #NSCLC #TEPMETKO #METex14